Skip to content

Booksellers & Trade Customers: Sign up for online bulk buying at trade.atlanticbooks.com for wholesale discounts

Booksellers: Create Account on our B2B Portal for wholesale discounts

Targeted Radionuclide Tumor Therapy: Biological Aspects

by Torgny Stigbrand
Save 35% Save 35%
Current price ₹13,583.00
Original price ₹20,896.00
Original price ₹20,896.00
Original price ₹20,896.00
(-35%)
₹13,583.00
Current price ₹13,583.00

Imported Edition - Ships in 18-21 Days

Free Shipping in India on orders above Rs. 500

Request Bulk Quantity Quote
+91
Book cover type: Paperback
  • ISBN13: 9789048179565
  • Binding: Paperback
  • Subject: N/A
  • Publisher: Springer
  • Publisher Imprint: Springer
  • Publication Date:
  • Pages: 402
  • Original Price: EUR 186.9
  • Language: English
  • Edition: N/A
  • Item Weight: 625 grams
  • BISAC Subject(s): Oncology / General, Diagnostic Imaging / General, and Radiology, Radiotherapy & Nuclear Medicine

From the Back Cover

The last three decades have provided opportunities to explore the potential of treating malignant diseases with antibodies or other targeting molecules labelled with nuclides. The expanding array of new targeting molecules (recombinant antibodies or peptides) may increase the therapeutic efficacy. The title of this book "Targeted Radionuclide Tumor Therapy - Biological aspects" was selected to reinforce the concept that a major focus was devoted to understanding the biological effects of targeting and radiation. Furthermore, our rapidly expanding knowledge of low dose-rate effects, different types of cell death, autosensitization and the increasingly likely existence of cancer stem cells suggests to us that even more efficient approaches in targeting might be possible in the future.

The development of targeted therapy is a true multidisciplinary enterprise involving physician scientists from the fields of nuclear medicine, radiation therapy, diagnostic radiology, surgery, gynaecology, pathology and medical oncology/haematology. It also involves many preclinical scientists working with experimental animal models, immunochemistry, recombinant antibody technologies, radiochemistry, radiation physics and basic cell biology.

It is the ambition of the editors to enable deeper insights in the process of improving targeted therapy. We believe that the time now has come when targeted therapy can soon be added to standard oncology treatment regimens.

Trusted for over 49 years

Family Owned Company

Secure Payment

All Major Credit Cards/Debit Cards/UPI & More Accepted

New & Authentic Products

India's Largest Distributor

Need Support?

Whatsapp Us